Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

93.04CHF
12:30pm EDT
Change (% chg)

CHF-0.12 (-0.13%)
Prev Close
CHF93.16
Open
CHF93.32
Day's High
CHF93.80
Day's Low
CHF92.66
Volume
4,138,431
Avg. Vol
5,129,834
52-wk High
CHF93.96
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.11
Market Cap(Mil.): CHF237,472.59
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.85
Yield (%): 3.01

Financials

  NOVN.S Industry Sector
P/E (TTM): 17.45 58.04 58.45
EPS (TTM): 5.34 -- --
ROI: 11.19 12.51 12.08
ROE: 16.51 13.49 13.20

Novartis says listing of Alcon eye care business expected on April 9

ZURICH Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss market and the New York Stock Exchange, the Swiss pharmaceuticals company said on Friday.

3:03am EDT

UPDATE 1-Novartis says listing of Alcon eye care business expected on April 9

ZURICH, March 22 Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss market and the New York Stock Exchange, the Swiss pharmaceuticals company said on Friday.

2:57am EDT

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

Mar 20 2019

UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

Mar 20 2019

BRIEF-Novartis' Alcon Acquires U.S. Medical Company For $285 Mln

* ACQUISITION FURTHERS ALCON'S COMMITMENT TO BRING THIS INNOVATIVE, ACCOMMODATING LENS TO CATARACT PATIENTS THROUGHOUT WORLD

Mar 18 2019

BRIEF-Novartis Late-Breaking Data Further Support Initiation Of Entresto In Hospital

* NOVARTIS LATE-BREAKING DATA FURTHER SUPPORT INITIATION OF ENTRESTO IN HOSPITAL AND AS FIRST-CHOICE SYSTOLIC HEART FAILURE THERAPY IN STABILIZED PATIENTS

Mar 16 2019

Novartis generics boss quits amid conjecture over business's future

ZURICH Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.

Mar 14 2019

Novartis names new CEO for Sandoz generics business

ZURICH, March 14 The chief executive of Sandoz, the generics business of Swiss drugmaker Novartis, is stepping down "for personal reasons", the company said on Thursday.

Mar 14 2019

Novartis has no plans to sell Sandoz: chairman

ZURICH Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business, Chairman Joerg Reinhardt said in a newspaper interview, saying it was keeping its options open.

Mar 05 2019

UPDATE 1-Novartis has no plans to sell Sandoz - chairman

ZURICH, March 5 Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business, Chairman Joerg Reinhardt said in a newspaper interview, saying it was keeping its options open.

Mar 05 2019

Earnings vs. Estimates